EAACI Congress 2024
BackOAS-CT02 - Clinical trials
Sunday 02 Jun, 15:00 PM -
16:30 PM Valencia, Spain
Innovation Hub
Oral Abstract Session on Clinical Trials
15:00
Comparative phase 2 bioavailability study of a fast acting, dry powder-based, epinephrine intra-nasal formulation, FMXIN002, for anaphylaxis
15:12
Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial
15:24
Long-Term Efficacy and Safety of Stapokibart in Patients with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Pivotal Phase 3 Trial
15:36
Identifying KIT D816V Mutation in Patients With Evidence of Systemic Mast Cell Activation (MCA) and Enriched for Hereditary Alpha-tryptasemia (HaT): Results From the PROSPECTOR Clinical Trial
15:48
Garadacimab improves quality of life in patients with hereditary angioedema: Results from the Phase 3 open-label extension study
16:00
A Study Conducted in the Environmental Exposure Chamber (EEC) to Assess Onset of Action of Combination of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Dymista) in the Treatment of Allergic Rhinitis Symptoms Compared to Placebo
16:12
Patients With Moderate-to-Severe Asthma Treated With Dupilumab Are More Likely to Meet Clinical Remission Criteria: Results From the VESTIGE Trial